Biopharma

Open Innovation Event Webinar

10:00 – 10:15 AM | Opening by Andy Topping, CSO, FUJIFILM Diosynth Biotechnologies 10:15 – 10:45 AM | Real Time Metabolomics in Biotechnology and Biopharma | Karl Burgess, Senior Lecturer...

Aug 06, 2020
10:00 am – 2:00 pm
Future of (how we) Work Task Force

Kendall Square Association’s (KSA) Future of (how we) Work Task Force answers critical questions about how our innovation ecosystem will return to work in a post-COVID-19 world. The Future of...

Jan 19, 2021
6:00 pm – 7:30 pm
- Biopharma
Biogen, placing a major bet on a once-failed treatment, is paying $1.53 billion for the commercial rights to a Sage Therapeutics’ oral depression drug, zuranolone.
- Biopharma
- Biotech + Life Sciences
Last week, Anne Heatherington, Ph.D., senior vice president and head of Data Sciences Institute at Takeda shared that competitive barriers that typically limit the sharing of data have been broken down during the global response.
- Biopharma
Johnson & Johnson entered its final stage of clinical trials for its COVID-19 vaccine. What differentiates their vaccine candidate from others is that it does not need to be frozen and may require just one injection.
- Biopharma
- Biotech + Life Sciences
Nine CEOs signed a pledge outlining a united commitment to sustain the integrity of the scientific process as they work toward potential regulatory filings and approvals of the first COVID-19 vaccines.
- Biopharma
- Biotech + Life Sciences
Bayer has entered a collaboration agreement with Recursion Pharmaceuticals to strengthen AI-guided drug discovery and advance new treatments for fibrotic diseases of the lung, kidney, heart, and more.
- Biopharma
Moderna CEO sees ‘high probability’ of success with Covid-19 vaccine

Recent history suggests a new vaccine entering human clinical trials has about a 1-in-3 chance of getting FDA approval. Stephane Bancel, chief executive of Moderna, pegs the chances of his company’s novel coronavirus vaccine at closer to 80% to 90%.